A Phase 1 interventional study of Indacaterol maleate and glycopyrronium bromide and Indacaterol maleate and glycopyrronium bromide in Healthy Volunteers, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-28.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess pharmacokinetics (PK) of indacaterol and glycopyrronium, and methodology and practical arrangements for future studies.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main inclusion criteria:
Main exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Indacaterol maleate and glycopyrronium bromide
Drug: Indacaterol maleate and glycopyrronium bromide · Drug: Ultibro Breezhaler with oral charcoal
Drug: Indacaterol maleate and glycopyrronium bromide
Drug: Indacaterol maleate and glycopyrronium bromide
Drug: Indacaterol maleate and glycopyrronium bromide
Drug pages: Indacaterol maleateStudies of Indacaterol maleateIndacaterol maleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Batch A Ultibro Breezhaler 85/43 μg 2 capsules
Drug pages: Indacaterol maleateStudies of Indacaterol maleateIndacaterol maleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Batch A Ultibro Breezhaler 85/43 μg 1 capsule
Drug pages: Indacaterol maleateStudies of Indacaterol maleateIndacaterol maleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Batch B Ultibro Breezhaler 85/43 μg 2 capsules
Activated charcoal suspension, granules 50 g / bottle
Peak indacaterol concentration in plasma (Cmax)
Time frame: between 0-72 hours after dosing
Peak glycopyrronium concentration in plasma (Cmax)
Time frame: between 0-72 hours after dosing
Indacaterol area under the concentration-time curve from time zero to 30 minutes (AUC30min)
Time frame: 0-30 minutes after dosing
Glycopyrronium area under the concentration-time curve from time zero to 30 minutes (AUC30min)
Time frame: 0-30 minutes after dosing
Indacaterol area under the concentration-time curve from time zero to 72 hours (AUC72h)
Time frame: 0-72 hours after dosing
Glycopyrronium area under the concentration-time curve from time zero to 72 hours (AUC72h)
Time frame: 0-72 hours after dosing
Indacaterol area under the concentration-time curve from time zero to the last sample with a quantifiable concentration (AUCt)
Time frame: 0-18 days after dosing
Glycopyrronium area under the concentration-time curve from time zero to the last sample with a quantifiable concentration (AUCt)
Time frame: 0-18 days after dosing
Indacaterol area under the concentration-time curve from time zero to infinity (AUCinf)
Time frame: 0-18 days after dosing
Glycopyrronium area under the concentration-time curve from time zero to infinity (AUCinf)
Time frame: 0-18 days after dosing
Time to reach peak indacaterol concentration in plasma
Time frame: between 0-72 hours after dosing
Time to reach peak glycopyrronium concentration in plasma
Time frame: between 0-72 hours after dosing
Indacaterol terminal elimination half-life (t1/2)
Time frame: 0-18 days after dosing
Glycopyrronium terminal elimination half-life (t1/2)
Time frame: 0-18 days after dosing
Number of adverse events as event counts and subjects counts
Time frame: throughout the study, average 9-12 weeks
Ran from May 2021 to primary completion in Sep 2021, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Indacaterol maleate · Glycopyrrolate
Orion Corporation, Orion Pharma →